A hedge fund allegedly banned its traders from taking Ozempic. The theory, as one tech investor put it: “GLP-1s reduce appetite for risk. They cause anhedonia. People’s personalities change. They stop drinking, gambling. It takes your edge away.”
I read that and felt my chest tighten. Because my father drank himself to death at 54. And what this man is calling “losing your edge” is what my father’s doctors spent two decades failing to give him.
He wanted to stop. Every detox, every AA meeting, every white-knuckled week of sobriety followed by the same collapse — he wanted to stop. The wanting wasn’t enough. His brain chemistry made the decision for him, every single time. And now there’s a class of drugs that might have changed that equation, and Silicon Valley is worried about trader performance.
Let me tell you what the actual data says about GLP-1s and addiction. Because this isn’t a side effect. This might be the most important thing these drugs do.
The Trial That Should Be Front-Page News
In early 2025, JAMA Psychiatry published the results of a phase II randomized controlled trial — NCT05520775 — testing low-dose semaglutide in 48 adults with alcohol use disorder. Not people in rehab. Not people who had hit bottom. Just people who drank too much and hadn’t sought treatment, which describes fewer than 10% of people with AUD ever do.
The doses were small. 0.25 mg per week for the first month, stepping up to 0.5 mg, then 1.0 mg. For context, the weight loss dose is 2.4 mg. These people were taking a fraction of what gets prescribed for obesity.
The results: semaglutide reduced alcohol consumption with a medium-to-large effect size (β = −0.48, 95% CI −0.85 to −0.11, P = .01). Heavy drinking days dropped. Drinks per drinking day dropped. Alcohol cravings dropped. Peak breath alcohol concentration dropped. And 96% of participants completed the trial — a completion rate that would make any addiction researcher weep with joy, because getting people to stick with treatment is half the battle.
Let me put that in human terms. People who weren’t even trying to quit drank less, wanted alcohol less, and stayed in the study. At a dose so low it wouldn’t cause meaningful weight loss.
What’s Actually Happening in the Brain
The “anhedonia” framing is a tell. It reveals that the person using it doesn’t understand the mechanism — or doesn’t want to.
GLP-1 receptors aren’t just in your gut. They’re densely expressed in the ventral tegmental area and nucleus accumbens — the brain’s reward circuit. When you drink, when you gamble, when you compulsively shop, these regions flood with dopamine. That surge is what makes the behavior feel essential, even when you know it’s destroying you.
GLP-1 receptor agonists modulate that circuit. They reduce the dopamine surge from addictive stimuli without flattening baseline reward processing. The technical distinction matters: they decrease “wanting” (the compulsive motivational drive) more than “liking” (the ability to enjoy things). They also increase dopamine transporter expression, essentially making the brain better at cleaning up excess dopamine rather than letting it pool and reinforce destructive patterns.
This is not anhedonia. Anhedonia is the inability to feel pleasure. What the research describes is the reduction of compulsive pleasure-seeking — the specific neural pattern that drives addiction. There is an enormous difference between not enjoying your life and not being enslaved by a bottle.
The List of Things People “Lose”
Alcohol. Cigarettes. Compulsive gambling. Binge eating. Impulsive shopping. Skin-picking. Nail-biting. The inability to walk past a bar without going in.
On Reddit, 29.75% of users discussing GLP-1s and alcohol report complete cessation. Not reduction — cessation. Almost a quarter of nicotine-related posts describe quitting. Twenty-one percent report interrupted impulsive shopping, replaced by planned purchases.
These are anecdotal, yes. But the clinical data is catching up. The JAMA Psychiatry trial confirmed fewer cigarettes per day among smokers in the semaglutide group. Preclinical studies in rodents show reduced self-administration and reinstatement of cocaine, amphetamines, alcohol, nicotine, and opioids. Multiple clinical trials are now underway — NCT05895643 is testing semaglutide specifically for co-occurring AUD and obesity.
A hedge fund manager hears “they stop gambling” and sees a business risk. An addiction specialist hears the same thing and sees a potential revolution in treatment.
The Women Nobody Is Talking About
Here’s where this gets personal for me as a health journalist who covers women’s health.
Women’s alcohol use disorder is rising faster than men’s, and it’s drastically underdiagnosed. Between 2016 and 2021, alcohol-related deaths rose 35% in women versus 27% in men. ER visits increased 70% for women versus 58% for men. Nearly 13% of reproductive-age women meet AUD criteria, but only 4-6% receive any treatment. Only 7.9% of women with AUD got help in recent years.
The reasons are exactly what you’d expect. Stigma. The “wine mom” culture that normalizes daily drinking while simultaneously shaming women who admit they can’t control it. Fear of child protective services. Co-occurring depression and anxiety — 47% of women with AUD have both. The telescoping effect, where women progress from moderate drinking to severe AUD faster than men.
And women metabolize alcohol differently. Liver damage, cognitive decline, and cancer risk accelerate at 1.8 drinks per day for women versus 3.2 for men. The biology is less forgiving. The social support is thinner. The treatment rates are lower.
Now imagine telling these women that a drug they might already be taking for weight management — at low doses, with good tolerability — could also quiet the voice that tells them to open that third bottle of wine after the kids go to bed. Imagine telling them this isn’t a side effect to be managed. It’s a feature.
Low Dose Is the Key Phrase
The trial used doses between 0.25 and 1.0 mg per week. The standard Ozempic weight-loss trajectory goes to 2.4 mg. The addiction benefit appeared at doses that would barely register on a weight loss chart.
This matters for two reasons. First, the side effects that make high-dose GLP-1s challenging — nausea, appetite suppression, GI issues — are minimal at these doses. The 96% completion rate in the JAMA trial reflects that. Second, it means people who don’t need or want significant weight loss could potentially benefit from the addiction modulation alone.
I’ve talked to researchers who believe the future of GLP-1 prescribing will include low-dose protocols specifically for addiction and compulsive behavior, completely separate from the obesity indication. We’re not there yet — we need larger trials, we need dose-response curves mapped for behavioral outcomes, we need long-term safety data at these lower doses. But the signal is strong enough that multiple major medical centers are running trials right now.
What “Losing Your Edge” Actually Means
Let me translate the hedge fund concern into plain language. “GLP-1s reduce appetite for risk” means: people stop making impulsive decisions driven by dopamine surges. In trading, maybe that costs you some alpha. In life, it might mean you don’t blow your paycheck at the casino, don’t drive home after five drinks, don’t text your ex at 2 AM, don’t buy things you can’t afford because the purchase briefly fills a void.
The framing reveals everything about who gets to define “normal.” If you’re a Wall Street trader, reduced risk appetite is a career threat. If you’re a 42-year-old mother hiding wine bottles in the recycling before your husband gets home, reduced risk appetite is the first morning you wake up without shame in three years.
My father never got that morning. He died with a blood alcohol level that would have killed most people, except his tolerance was so high his body had adapted to being poisoned. The disease took everything from him in stages — his job, his marriage, his relationship with his kids, his dignity, and finally his life. At every stage, someone in his brain was screaming to stop. The dopamine circuit screamed louder.
If a drug could have turned that volume down — not off, not into numbness, but down enough for him to hear his own voice — I don’t care what it does to a trader’s quarterly returns.
What This Means for People Considering GLP-1s
If you’re taking a GLP-1 for weight management and you’ve noticed you drink less, shop less impulsively, or feel less pulled toward compulsive behaviors — that’s not a side effect. The mechanism is doing exactly what the neuroscience predicts. You’re not broken. You’re not losing yourself. Your reward circuit is recalibrating.
If you’re someone who struggles with alcohol or compulsive behavior and you’re interested in GLP-1s specifically for this — the clinical evidence is early but real. The JAMA Psychiatry trial used semaglutide, which is available as a research peptide at significantly lower cost than branded Ozempic. At the low doses used in the addiction research (0.25-1.0 mg/week), a single vial can last months. The research community has been using these compounds to explore exactly these low-dose applications, and at these precise low doses, compound purity matters enormously — the difference between a 62% and 99.9% pure vial changes your actual dose by nearly half.
If you’re a woman dealing with AUD or compulsive behavior, know this: you are not alone in a way that statistics can barely capture. Thirteen percent of reproductive-age women meet the criteria. Seven percent get help. The gap between those numbers is an ocean of quiet suffering, and if there’s a pharmacological tool that can help bridge it — at low cost, at low doses, with the weight management benefit as a bonus rather than the primary purpose — that deserves your attention, not your fear.
The Real Question Nobody Is Asking
The debate about GLP-1s and personality is real, and I don’t dismiss people who feel different on these drugs. If you’re experiencing genuine anhedonia — flattened emotions, loss of interest in things you used to love, inability to feel joy — talk to your doctor about dose adjustment. That’s a real side effect that deserves attention, particularly at higher doses and particularly in people with a history of depression.
But the conversation right now is being driven by people who have the luxury of worrying about their “edge.” It’s being driven by tech investors and hedge fund managers and productivity optimizers. Meanwhile, 28.3 million Americans have alcohol use disorder. 480,000 die from smoking every year. The opioid crisis kills 80,000 annually. And a class of drugs is showing consistent, replicated, mechanistically logical evidence that it can modulate the exact brain circuit driving all of these — and the loudest voices in the room are worried about whether it’ll hurt their Sharpe ratio.
My father would have traded every edge he ever had for one more year. He didn’t get the choice. But for the millions of people who are quietly losing the same war he lost — the data says there might be a new weapon in the fight. At low doses. With manageable side effects. With a mechanism we actually understand.
That’s not anhedonia. That’s hope.
References
- Klausen MK, et al. “Semaglutide for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.” JAMA Psychiatry, 2025. NCT05520775.
- Hernandez NS, Schmidt HD. “Central GLP-1 receptor signaling and dopamine-mediated reward.” Pharmacology, Biochemistry and Behavior, 2019.
- Vallöf D, et al. “Brain region-specific GLP-1 receptor signaling reduces alcohol intake.” Addiction Biology, 2019.
- White AM, et al. “Alcohol-Related Deaths During the COVID-19 Pandemic.” JAMA, 2022.
- Agabio R, et al. “Sex Differences in Alcohol Use Disorder.” Current Medicinal Chemistry, 2017.
- NCT05895643 — Phase 2 Trial: Semaglutide for Co-occurring AUD and Obesity. ClinicalTrials.gov.